Skip to main content
Premium Trial:

Request an Annual Quote

Sangamo and Millennium Sign Research Agreement

Premium

POINT RICHMOND, Calif.--Sangamo BioSciences, a privately held biotechnology company here, announced that it has signed a collaborative research agreement with Millennium Pharmaceuticals in which Millennium will pay the company to evaluate Sangamo's Universal GeneTools product in the validation of gene targets for drug discovery.

Sangamo's technology platform enables the rational design and rapid generation of highly specific zinc finger DNA recognition proteins that can selectively recognize and regulate any target gene or DNA sequence. Engineered zinc finger proteins are used to accelerate the functional analysis of newly discovered genes and to validate clinically relevant gene targets.

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.